Outset Medical, Inc. is a medical technology company that develops the Tablo Hemodialysis System, a single enterprise solution for hemodialysis. The company's primary product, Tablo, is an FDA-cleared compact console that integrates water purification, on-demand dialysate production, and advanced software capabilities. Tablo is designed to operate in hospital, clinic, and home settings, requiring only a standard electrical outlet and tap water. The system includes the Tablo Console, a proprietary disposable Tablo Cartridge for treatment setup, and the Tablo Data Ecosystem, which provides cloud-based remote monitoring, patient analytics, and automated clinical recordkeeping. Outset Medical serves acute-care facilities, skilled nursing facilities, long-term acute care hospitals, and home dialysis patients across the United States. The company supports healthcare providers in establishing insourced dialysis service lines and offers field service, sales, and clinical support teams to facilitate device adoption and utilization.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage outsetmedical.com
Sector Healthcare IR page investors.outsetmedical.com
Tags
hemodialysis, renal care, acute care, home dialysis, dialysis systems, clinical analytics, medical technology, Tablo, Tablo Hemodialysis System, Tablo Console, Tablo Cartridge, Tablo Data Ecosystem, TabloCart
Press page —

Metrics

Valuation  
Market cap $ 69.264M
Market cap (USD) $ 69.264M
P/E -0.97
PEG —
P/BV 0.83
P/S 0.57
P/OCF -1.63
P/FCF -1.62
Dividend yield —
Turnover / mcap —
Returns  
ROE -106.2%
ROI -36.6%
ROIC -22.4%
Profit margin -68.3%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity 118.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 119.476M 113.689M 130.376M 115.375M 102.602M 49.935M 15.078M
Net profit -81.653M -127.976M -172.797M -162.956M -131.935M -121.492M -68.299M
Free cash flow -47.125M -117.215M -134.813M -154.054M -133.372M -108.123M -73.585M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 3.71 1.11 5.41 25.82 46.09 56.84 —
Price performance 12m 2.34 -0.79 -0.79 -0.44 -0.19 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 3.91M 6.47M 25.6M 28.1M 33M 35.6M 28.3M
↳ YoY growth +65.3% +295.8% +9.6% +17.5% +8.0% -20.5%
↳ 5y CAGR +55.5% +34.4%
Borrowings, current (USD) — 7.5M 2.03M 2.03M 4.75M — — —
Borrowings, non-current (USD) — 21.6M 29.7M 29.8M 96.3M 130M 197M 96.2M
Lease liabilities (USD) — 9,000 8.93M 8.04M 6.89M 6.08M 4.48M 5.01M
Cash and deposits (USD) — 36.9M 295M 182M 73.2M 68.5M 124M 35M
Right-of-use assets (USD) — — 8.25M 7.23M 6.12M 5.38M 3.94M 4.8M
Net debt (borrowings + leases - cash) (USD) — -7.87M -254M -143M 34.8M 67.7M 77.8M 66.2M
Cash flow detail
Operating cash flow (USD) -46.4M -70.3M -99M -130M -146M -131M -116M -46.3M
Purchases of property, plant and equipment (USD) -1.77M -3.29M -9.11M -3.11M -8.33M -3.44M -912,000 -798,000
Change in receivables (cash effect) (USD) -552,000 -2.89M -2.57M -19.1M -2.51M -5.09M -5.01M 3.78M
Change in inventories (cash effect) (USD) -2.21M -5.02M -16.3M -22M -14.7M 1.65M -10.9M 11.8M
Change in payables (cash effect) (USD) 2.68M 802,000 737,000 -3.07M -1.28M 5.31M -1.95M -3.29M
Interest paid (cash effect) (USD) -3.29M -3.35M -3.27M -1.15M -3.19M -10.8M -20.7M -15.6M
Income taxes paid (cash effect) (USD) -9,000 -35,000 -19,000 -83,000 -385,000 -491,000 -593,000 -447,000
Share-based compensation (USD) 788,000 883,000 21.4M 17.4M 27.2M 38.6M 29.4M 15.6M
Operating cash flow before change in receivables (USD) -45.9M -67.4M -96.4M -111M -143M -126M -111M -50.1M
Free cash flow (OCF - PPE - intangibles) (USD) -48.2M -73.6M -108M -133M -154M -135M -117M -47.1M
Income detail
Research and development expense (USD) 22.9M 23.3M 28.9M 36.7M 48.9M 57.3M 38.4M 21.2M
↳ 5y CAGR +20.1% +10.5% -5.9%
Total comprehensive income (USD) -49.8M -68.2M -122M -132M -163M -172M -128M -81.5M
Comprehensive income to owners (USD) -49.8M -68.2M -122M -132M -163M -172M -128M -81.5M
Provision for credit losses (USD) — 59,000 12,000 5,000 — — — —
Credit cost ratio (credit losses / average receivables) (%) — — 0.2% 0.0% — — — —
Reported Mar 22, 2021 Mar 22, 2021 Mar 22, 2021 Feb 23, 2022 Feb 13, 2023 Feb 21, 2024 Feb 28, 2025 Feb 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Outset Medical Reports Third Quarter 2026 Results Bull 3 Bear 0 Results

San Jose, CA – November 4, 2026 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter and Recent Highlights

•Net revenue totaled $33.6 million, an increase of 14% compared to the prior-year period and an increase of 6% sequentially.

•Console revenue of $10.5 million, an increase of 26% compared to the prior-year period and an increase of 10% sequentially.

•Recurring revenue, consisting of Tablo consumables and services, was $23.1 million, an increase of 10% compared to the prior-year period and an increase of 4% sequentially.

•Gross margin expanded to 40.7%, an increase of 130 basis points compared to the prior-year period.

•Net cash used during the quarter was $10.3 million, resulting in a total cash, cash equivalents, short-term investments and restricted cash position of $140.7 million at quarter end.

October 27, 2026

PDF Version

SAN JOSE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will participate in a fireside chat at the 2026 Stifel Healthcare conference on Tuesday, November 10, 2026, at 1:20 p.m. ET.

A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.

About Outset Medical, Inc. Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.

Investor Contact [email protected]

Primary Logo

Company Logo

Privacy Preference Center

  • Your Privacy

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functionality Cookies

  • Social Media Cookies

  • Targeting Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

User ID: a131cf31-46c2-4683-9f58-0bce357604cd

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Functionality Cookies

Functionality Cookies

These cookies enable the website to provide enhanced functionality and personalization. Functionality cookies allow a website to remember choices users make (such as a user’s username, language, or the region). They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Social Media Cookies

Social Media Cookies

These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They store uniquely identifying information about your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

checkbox label label

Apply Cancel

Allow All

Powered by Onetrust

October 21, 2026

PDF Version

SAN JOSE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter 2026 after the close of trading on Wednesday, November 4, 2026.

On the same day, at 1:30 p.m. PT (4:30 p.m. ET), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss the results.

Conference Call Details Those interested in accessing the live or archived version of the conference call can visit the “Investors” section of the Outset Medical website at https://investors.outsetmedical.com.

Those interested in participating in the call via telephone are encouraged to register more than 15 minutes before the start of the call via the following link: https://register-conf.media-server.com/register/BIf6886fe8d04a44bbbb5a5da8650079ac. Once registered, participants will receive a dial-in number and unique PIN to join the call.

About Outset Medical, Inc. Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.

Investor Contact [email protected]

Primary Logo

Company Logo

Privacy Preference Center

  • Your Privacy

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functionality Cookies

  • Social Media Cookies

  • Targeting Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

User ID: c0a8a794-7865-4f54-8dad-a5fd9b001e31

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Functionality Cookies

Functionality Cookies

These cookies enable the website to provide enhanced functionality and personalization. Functionality cookies allow a website to remember choices users make (such as a user’s username, language, or the region). They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Social Media Cookies

Social Media Cookies

These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They store uniquely identifying information about your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

checkbox label label

Apply Cancel

Allow All

Powered by Onetrust

Prompts

Outset Medical, Inc. (ticker OM), listed in United States.

Company History

Date Change Detail
May 19, 2015 Renamed Home Dialysis Plus, Ltd. → OUTSET MEDICAL, INC.

ETFs Holding Outset Medical, Inc.

ETF Weight in ETF Shares Market value As of
FMED 0.25% 34,000 $ 129.88K Aug 31, 2026
DFSU 0.00% 6,708 $ 25.893K Nov 12, 2026
DFAS 0.00% 50,068 $ 193.262K Nov 12, 2026
DFAC 0.00% 24,331 $ 93.918K Nov 12, 2026
AVSC 0.00% 26,735 $ 90.632K Nov 16, 2026